key: cord-1009502-eltybvsi authors: Richardson, C.; Gildea, S.; Harkin, S.; Gallagher, A.; Conroy, E.; McClafferty, L.; McCole, E.; Benchikh, E. O.; Reid, C. N.; Dunlop, M.; Savage, S.; Lowry, P.; Curry, J.; McConnell, R. I.; Lamont, J. V.; FitzGerald, S. P. title: Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) date: 2021-06-03 journal: nan DOI: 10.1101/2021.06.03.21255116 sha: adaf8c221a4ba9ba7bcee2bfbfd36e20a3921a48 doc_id: 1009502 cord_uid: eltybvsi The urgent need for a rapid and reliable Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) neutralising antibody detection test compatible with routine clinical laboratory testing currently exists. This is necessary to provide accurate estimates of immunity and to monitor vaccine effectiveness. Utilising Biochip Array Technology (BAT), the Randox SARS-CoV-2 Biochip proxy virus neutralisation test (pVNT) has been developed. Immobilising SARS-CoV-2 Spike RBD on the Biochip surface, innovative assay design enables direct sample addition to the Biochip well without the need for off-board sample pre-incubation step. Results are reported within 1.5 hours and testing is carried out without the prerequisite of live virus or biosafety level 3 (BSL3) laboratory facilities. In this study, assay validation is performed using recombinant antibodies and clinical samples and an excellent correlation against conventional virus neutralisation methods is established (100% clinical specificity and 98% clinical sensitivity). Serial dilution of samples with high neutralising antibody levels demonstrate end-point sample dilutions comparable with those obtained using the SARS-CoV-2 microneutralisation test. Species independent neutralising antibody detection capacity of the SARS-CoV-2 Biochip pVNT is also demonstrated. The findings of this study exemplifying the utility of the SARS-CoV-2 Biochip pVNT as a robust and reliable method for the accurate measurement of neutralising antibodies against SARS-CoV-2 and the availability of this test can now positively impact current testing deficiencies in this area. Coronavirus Disease 2019 which is caused by SARS-CoV-2 infection was first recognized in December 2019 in Wuhan, China 1 . On 30 th January 2020, The World Health Organization (WHO) stated that COVID-19 constituted a "public health emergency of international concern", latterly, on 11 th March, it was declared a pandemic. Infection is initiated when the viral trimeric Spike (S) protein binds to ACE2 subsequently, proteolytic cleavage of the S protein by TMPRSS2 or cathepsin L mediates viral entry 2 . Molecular detection using polymerase chain reaction (PCR) continues to play a pivotal role enabling "gold standard" diagnostic testing while next-generation sequencing is being increasingly deployed to monitor genetic variants that are arising globally 3. The recently emergent variants; UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. exhibit multiple mutations in the immunodominant Spike protein RBD and these constitute significant concern for their potential to induce immune evasion 4 . This has significant implications for the ongoing global effort to produce effective vaccines and the concept of establishing societal immunity 5 . The gold standard virus neutralisation test (VNT) which detect neutralising antibodies in a subject's blood sample must be completed in a specialized BSL3 containment laboratory because it uses infectious SARS-CoV-2 virus with live cell invasion; the test format is laborious taking 2-4 days to complete 6 . Deployment of pseudovirus-based virus neutralisation tests which can be completed with biosafety level 2 (BSL2) containment are equally tedious and time consuming 7 . Consequently, there is an urgent need to develop a rapid, reliable serological based SARS-CoV-2 neutralising antibody detection immunoassay. In this study, we report the development of a rapid proxy virus neutralisation test (pVNT) using Randox's proprietary BAT, which can detect SARS-CoV-2 neutralising antibodies in a subject's blood sample compatible with routine clinical laboratory testing. The in vitro pVNT concept is based on the in vivo interaction of spike protein RBD with ACE2; this highly specific protein-protein interaction will be blocked if a subject has developed an antibody repertoire that prevents the interaction between spike protein RBD and ACE2 i.e. neutralising antibodies. Our rapid pVNT format mimics that of the classic VNT with results generated within 1.5 hours. Human and animal samples Seronegative human serum and plasma samples were collected from individuals pre COVID-19 (before October 2019). Seropositive human serum and plasma samples were collected from SARS-CoV-2 patients at fixed time points following RT-PCR confirmation of SARS-CoV-2 infection. Human serum and plasma samples containing antibodies against endemic human coronaviruses (HKU1, OC43, 229E, NL63) and other non-coronavirus related pathogens were also collected. Sheep antisera was collected following immunisation with SARS-CoV-2 Spike RBD (GenScript, Z03483) and SARS-CoV-2 Nucleocapsid protein (GenScript, Z03488). Samples were collected on the day of immunisation followed by 3, 6, 10, 13, 20, 28 and 52 days post immunisation. Immunisation and the collection of samples from sheep was carried out under Animals (Scientific Procedures) Act 1986 -Project License number PPL2797. Humanised IgG recombinant antibodies SARS-CoV-1 RBD Antibody 1 (RAB0001), SARS-CoV-1 RBD Antibody 2 (RAB0003), SARS-CoV-2 RBD Antibody 1 (RAB0006) and SARS-CoV-2 RBD Antibody 2 (RAB0005) were supplied by Randox Laboratories Ltd. Sample characterisation using SARS-CoV-2 microneutralisation assay Two-fold serial dilution of sample was mixed 1:1 with SARS-CoV-2 virus (Germany/BavPat1/2020) and pre-incubated at 37°C for 1 hour to allow neutralisation. The virus-sample mixture was transferred into Vero-E6 cells monolayers and incubated at 37°C for 1 hour. One-hour post-infection, the inoculum was replenished with fresh growth medium and plates were incubated overnight after which the Vero-E6 cells were fixed and immunostained to visualise infected cells. MN80 titres were calculated according to the method described by Zielinski et al 8 and based on three sample replicates. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. antigen located at a discrete test region (DTR). SARS-CoV-2 neutralising antibodies if present, will bind RBD, inhibiting its ability to interact with ACE2 labelled horseradish peroxidase (ACE2 HRP). Light signal generated from the RBD immobilised DTR is detected using digital imaging technology as previously described 9 and is inversely proportional to the amount of SARS-CoV-2 neutralising antibody present in a sample. Briefly, 288μL assay diluent and 12μL sample or positive/negative control (1/25 in Biochip well sample dilution) were applied directly to the Biochip. After incubation at 37 °C and 370 rpm for 30 min on a thermoshaker (EV702-527, Randox Laboratories Ltd), the supernatant was discarded. Following two quick and four 2-min washing cycles, 300μL of ACE2 HRP was added to each well and incubated at 37 °C and 370 rpm for 30 min. After a second wash cycle (same as above), 250μL signal reagent (1:1 mixture of peroxide/ luminol solution) was added to each Biochip well and incubated for 2 min in the dark. Emitted light from the RBD antigen immobilised DTR was detected by a charged coupled device (CCD) camera and signal was quantified using the Evidence Investigator System and its imaging processing software. Percentage inhibition (% inhibition) was calculated for each sample relative to the negative control. Samples with % inhibition > 50% are reported as seropositive for SARS-CoV-2 neutralising antibodies. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In the present study, an assay format utilising ACE2 antigen (Randox Laboratories Ltd, RCP9642) immobilised on the Biochip was also explored. Briefly, sample or positive/negative control was incubated off-board at a ratio of 16μL to 384μL assay diluent containing RBD (Randox Laboratories Ltd, RCP9639) labelled with HRP for 30 minutes at 37 °C. Following incubation 300μL of this preparation was added to the Biochip well containing immobilised ACE2 and incubated at 37 °C and 370 rpm for 30 min on a thermoshaker. Following two quick and four 2-min washing cycles, 250μL signal reagent (1:1 mixture of peroxide/ luminol solution) was added to each well and incubated for 2 min in the dark. Emitted light from the ACE2 antigen immobilised DTR was detected by a CCD camera, and signal was quantified using the Evidence Investigator System and its imaging processing software. Percentage inhibition (% inhibition) was calculated for each sample relative to the negative control. The correlation between the SARS-CoV-2 Biochip pVNT and SARS-CoV-2 microneutralisation assay was calculated with Pearson's correlation coefficients on MedCalc version 19.0.4. using logarithmically SARS-CoV-2 microneutralisation transformed assay data. Employing BAT, we demonstrated functional interaction between ACE2 immobilized on the Biochip surface and HRP labelled RBD ( Figure 1A , Table 1A) . Furthermore, it was demonstrated that this interaction could be disrupted using various recombinant neutralising antibodies as well as SARS-CoV-2 RBD IgG seropositive samples. Two SARS-CoV-1 RBD antibodies (SARS-CoV-1 RBD Antibody 1, SARS-CoV-1 RBD Antibody 2) exhibited 36.0% and 98.5% inhibition respectively whereas two SARS-CoV-2 RBD antibodies (SARS-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2021. (Table 1B) . It was decided to proceed with development of a pVNT that exploits the interaction between RBD and ACE2 whereby RBD is immobilized on the Biochip surface as opposed to ACE2. Stepwise disruption of RBD/ACE2 interaction using two recombinant neutralising antibodies Dilutional linearity assessment of the SARS-CoV-2 Biochip pVNT All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2021. An overall correlation coefficient r=0.9355 was obtained when comparing sample classification using both methodologies demonstrating highly comparable performance between both testing approaches. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Proof of principle demonstration of species independent applicability of the SARS-CoV-2 Biochip pVNT Antisera collected from sheep immunized with either SARS-CoV-2 Nucleocapsid protein or SARS-CoV-2 Spike RBD were utilized to investigate potential species independent applicability of the SARS-CoV-2 Biochip pVNT. Antisera was collected at timepoints ranging from day 0 to day 52 post immunization and applied to the SARS-CoV-2 Biochip pVNT (Table 4 ). Interestingly, antisera from sheep immunized with RBD at day 52 exhibited 100.0% inhibition of the RBD/ACE2 interaction. Antisera from earlier timepoints appear negative for neutralising antibodies exhibiting 28.8% inhibition at day 6 for example. The specificity of this experimental approach was demonstrated by the observation that antisera from sheep immunized with Nucleocapsid protein were consistently negative for neutralising antibodies at all timepoints evaluated (0-52 days). This data strongly indicates the species independent applicability of the newly developed SARS-CoV-2 Biochip pVNT. Randox has developed a rapid Biochip pVNT for the detection of neutralising antibodies against SARS-CoV-2 amendable to high throughput testing in a routine clinical laboratory setting. This contrasts classical virus neutralisation antibody detection methods whereby barriers to rapid and high throughput testing include the requirement for live virus utilisation, highly trained laboratory personnel and BSL3 facilities 10 . The SARS-CoV-2 Biochip pVNT can deliver results within 1.5 hours compared to the 2-4 days required for the virus neutralisation test. Given that antibodies targeting SARS-CoV-2 Spike RBD account for >90% neutralising antibody activity in convalescent sera [11] [12] and that neutralising antibodies largely correlate with protection 13-14 , the widespread availability of rapid and amenable neutralising antibody tests is necessary to accurately ascertain measurements of global herd immunity post natural infection and vaccination. This is fundamental in accurately quantifying risk of infection and onwards virus transmission. Current sero-surveillance is primarily carried out using SARS-CoV-2 serology tests which can be either IgG specific or measure total Ig (IgG, IgA, IgM) levels. This strategy, while worthwhile, has some limitations as such approaches cannot differentiate neutralising from non-neutralising antibodies and results obtained do not equate to protective immunity. Therefore, the SARS-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CoV-2 Biochip pVNT test described in this study can positively impact current testing deficiencies in this area. have demonstrated that it is the RBD within the Spike protein of SARS-CoV-2 that interacts with ACE2 to precipitate viral entry 15 . During this study, we explored a pVNT format whereby ACE2 was immobilised on the Biochip surface and an alternative pVNT assay format whereby Spike RBD was immobilised on the Biochip surface. Good agreement in the detection of neutralising antibodies against SARS-CoV-2 was observed as demonstrated using recombinant neutralising antibodies and SARS-CoV-2 seropositive clinical samples. (Table 1A, In this study an excellent correlation between the SARS-CoV-2 Biochip pVNT and the SARS-CoV-2 microneutralisation test was observed. All 60 SARS-CoV-2 seronegative samples included in the correlation evaluation along with all 169 potential cross reactant samples were classified correctly using the SARS-CoV-2 Biochip pVNT. Forty nine of the 50 samples classified as seropositive using the SARS-CoV-2 microneutralisation assay were also detected using the SARS-CoV-2 Biochip pVNT. The single discordant sample which was a weak positive using the SARS-CoV-2 microneutralisation assay reported 47% inhibition using the SARS-CoV-2 Biochip pVNT thus just below the pVNT assay threshold (50%). The serial dilution of four samples (Figure 3 ) with high neutralising antibody levels reported an end-point dilution using the SARS-CoV-2 Biochip comparable with that obtained using the SARS-CoV-2 microneutralisation test. This demonstrates the potential of the SARS-CoV-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 1b: Result obtained with SARS-CoV-2 RBD immobilised on Biochip. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 1b: SARS-CoV-2 Spike RBD immobilised on Biochip. Anti-SARS-CoV-2 neutralising antibodies block ACE2 HRP from binding to SARS-CoV-2 RBD on Biochip. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.03.21255116 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.03.21255116 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.03.21255116 doi: medRxiv preprint 2020) A novel coronavirus outbreak of global health concern Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics Understanding variants of SARS-CoV-2 Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerging microbes & infections 9 Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis. Virology journal 2, 84. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder Development of a high-throughput automated analyzer using biochip array technology A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers Coronavirus Spike Protein and Tropism Changes Possible Bat Origin of Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility of white-tailed deer (Odocoileus virginianus) to SARS-CoV-2 Infection of dogs with SARS-CoV-2 Hakzevan der Honing, R.W. et al (2020) SARS-CoV-2 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 25 Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model From People to Panthera: Natural SARS-CoV-2 Infection in Tigers and Lions at the Bronx Zoo A serological survey of severe acute respiratory syndrome coronavirus 2 in in uhan Potently Neutralizing Antibody Protects Mice against SARS-CoV Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B